High Tissue Tumor Mutational Burden May Be Predictive of Improved Immunotherapy Efficacy
Data from previous studies evaluating the efficacy of atezolizumab, a PD-L1 inhibitor, have suggested that high tissue tumor mutational burden may be predictive of efficacy for checkpoint immunotherapy.